Search the Community

Showing results for tags 'neuroendocrine tumors'.

  • Search By Tags

    Type tags separated by commas.

  • Search By Author

Content Type


Forums

  • Biotech Stocks
    • General Biotech Investing Discussion
    • Daily Biotech Stock News
    • Biotech Forecast Course Discussion
  • Clinical, Regulatory and Company Catalysts
    • Event Tracker Discussion
    • Suggest Events to Add to the Event Tracker
  • BiotechForecast.com Site Updates, Announcements, & Questions
    • Site Updates & Announcements

Find results in...

Find results that contain...


Date Created

  • Start

    End

Last Updated

  • Start

    End

Filter by number of...

Joined

  • Start

    End

Group

About Me

Found 2 results

  1. Biotech_Forecast
  2. Biotech_Forecast
    Saint-Genis-Pouilly, France - June 27, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review for Lutathera, a Lu-177-labeled somatostatin analogue peptide currently under development for the treatment of gastro entero pancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. The Prescription Drug User Fee Act (PDUFA) target action date is December 28, 2016.